Nephrogenex: Jefferies Global Healthcare Conference (Nephrogenex) - Jun 8, 2014 - "NephroGenex Phase 2b PYR-210"; "Established SOC patients approved by FDA for phase 3"; "Patients on established (or stable) standard of care (SOC) at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAL patient population"; "Patient not on SOC at screening exhibited higher initial blood pressures, more frequent medication changes, and drops in blood pressure during treatment, confounding SCr measurements (overall study did not meet end point)"; "Pyridorin was well tolerated, had a benign safety profile (see Appendix), and slowed the rate of SCr increase in patients on stable SOC at screening" "
P2 data • Diabetic Nephropathy • Renal Disease
|